LTBR-enhanced CAR T-cell therapy for relapsed or refractory B‑cell lymphoma
Official title: LTBR CARs as next-generation therapies for R/R lymphoma
Funded at New York Genome Center · NIH-11311797 · Data updated 2026-11-12
The team will make CAR T-cells that carry LTBR to help people with relapsed or refractory diffuse large B‑cell lymphoma get stronger, longer-lasting responses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York Genome Center NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 10, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $819,260 |
| NIH project number | 5R01CA279135-04 |
| Project ID | NIH-11311797 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with relapsed or refractory diffuse large B‑cell lymphoma, particularly those eligible for CD19-directed CAR T-cell therapy or willing to donate blood or tumor samples, would be the ideal candidates.
✕Less likely to help
People with non–B‑cell cancers, those whose DLBCL is controlled by first-line treatment, or those ineligible for CAR T procedures would likely not benefit directly from this work.
What this research studies
You would be contributing blood or tumor samples so researchers can compare immune cell activity in newly diagnosed versus relapsed DLBCL. They will use single-cell profiling and lab tests to measure T-cell activation, exhaustion, and supporting myeloid cells. Scientists will engineer patients' autologous CAR T-cells to express LTBR and test those cells in functional assays and animal models to see if they kill lymphoma more effectively. If the lab and preclinical results are promising, the work could lead to clinical testing of LTBR-enhanced CAR T therapies.
Why it matters
Potential benefit: This approach could increase the number of people who get long-term remissions and extend survival after relapsed DLBCL.
How similar studies have gone: CD19-directed CAR T therapies have cured some patients with relapsed DLBCL but only about 35% achieve durable remission, and LTBR modification is a novel strategy that has shown promise in preclinical lab and animal studies but not yet in humans.
Where this research is happening
-
New York Genome Center
New York, United States Active
Researchers
- Principal investigator: Sanjana, Neville — New York Genome Center
- Study coordinator: Sanjana, Neville
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Targeting the IL-1R Pathway to Boost Immunotherapy for Anaplastic Large Cell Lymphoma
Aims to make CD30 CAR therapies work better for people with ALCL by blocking a immune-evasion pathway.
-
Radiation Therapy Innovation to Improve Lymphoma Trials and Carbon Ion Research Path
A Mayo Clinic-led effort to better design and run lymphoma trials by integrating advanced radiation therapy and exploring carbon ion radiotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.